1) Experimental drug 
Brasofensine (NS-2214, BMS-204756) is a phenyltropane that had been under development for the treatment of Parkinson`s and Alzheimer`s disease. Phase II trials were conducted in 1996 and brasofensine was shown to be both effective and well tolerated at a dose of 4 mg, however development was stopped after in vivo cis-anti isomerization of the 2